SNBL (Shin Nippon Biomedical Laboratories)

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (SNBL) is a group of companies that can undertake all stages of nonclinical studies and clinical bioanalysis. This page outlines the features of SNBL’s nonclinical studies, an example of a disease model, and case studies. Use the following information as a reference when selecting a contract research organization (CRO).

Features of SNBL’s Contract Non-Clinical Study Services

Extensive Experience and Proven Track Record

Since its establishment in 1957, SNBL has maintained a leading share in Japan in contract nonclinical testing. Leveraging extensive experience in drug development and continued investment in new equipment, SNBL is recognized by pharmaceutical companies as a trusted development partner. In particular, SNBL demonstrates high accuracy in evaluating the efficacy and safety of new drug candidates and provides data in a timely manner.

In-group NHP supply

SNBL breeds and supplies non-human primates (NHPs) within its corporate group. For emerging modalities such as nucleic acid therapeutics and gene therapies, SNBL can reliably supply animal models required for development.

Diverse disease models

SNBL conducts nonclinical studies using a diverse portfolio of disease models. In particular, SNBL has developed ocular disease models, including glaucoma and age-related macular degeneration (AMD), and has strong capabilities in efficacy/pharmacology studies using these models. The company is also advancing development of an intranasal (IN) drug-delivery system utilizing nose-to-brain technology and is engaged in brain disease model research.

Example Disease Models Maintained by SNBL

It is essential to go through the testing of candidate compounds in animal models that reproduce the target disease before advancing to clinical trials.

However, clinically relevant disease models may not always exist, thus there are demands for animal models with strong clinical correlation.

Below are some examples of disease models offered at Ina Research.

Monkey Disease Models of Glaucoma and Age-Related Macular Degeneration (AMD)

SNBL conducts nonclinical studies using various disease models. In particular, SNBL has developed monkey models of glaucoma and age-related macular degeneration and conducts contract efficacy/pharmacology studies using these models, supporting pharmaceutical companies in the development of new therapeutics for these diseases.

SNBL has also developed an intranasal drug-delivery system (N2B-system) that utilizes nose-to-brain technology and is advancing brain disease model research. This approach addresses the challenge of limited drug transfer to the brain and broadens the possibilities for new drug development.

SNBL Non-Clinical Case Studies

Specific examples include the following projects

Ocular diseases

SNBL offers efficacy/pharmacology studies using monkey models of glaucoma and age-related macular degeneration, enabling efficient development of new therapeutics for these ocular diseases.

Central nervous system (CNS) diseases using intranasal delivery technology

SNBL utilizes nose-to-brain (N2B-system) intranasal delivery to evaluate drug transfer to the brain. This technology enables delivery of agents that do not readily cross the blood–brain barrier, contributing to the development of new drugs for CNS diseases, such as Alzheimer’s disease and Parkinson’s disease, for example.

Corporate Information of SNBL

SNBL is a contract research organization (CRO) that primarily provides support for drug development, offering preclinical testing and drug analysis.

It also develops translational research projects and medical and health-related projects called Medipolis projects. In this way, SNBL supports pharmaceutical companies and medical institutions, contributing to the improvement of medical technology.